Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Metastatic Breast Cancer

Journal Scan / Research · August 30, 2024

Epidemiology of Early vs Late Recurrence Among Women With Early-Stage ER+ Breast Cancer

Journal of the National Cancer Institute

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Lillie Shockney RN, BS, MAS, HON-ONN-CG

Journal of the National Cancer Institute

Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study

J. Natl. Cancer Inst 2024 Jun 06;[EPub Ahead of Print], AV Chua, H Sheng, E Liang, S Gandhi, ML Kwan, IJ Ergas, JM Roh, CA Laurent, L Yan, T Khoury, CB Ambrosone, LH Kushi, S Yao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Metastatic Breast Cancer

Epidemiology of Early vs Late Recurrence Among Women With Early-Stage ER+ Breast Cancer

Additional Info

Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study

Further Reading

Safety of Alpelisib Combined With Capecitabine in Patients With HER2− Metastatic Breast Cancer

Outcomes of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and Clinical Subgroups

Diagnostic Accuracy of ESR1 Mutation Detection in Breast Cancer Using Cell-Free DNA

Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy vs Placebo Plus Endocrine Therapy for HR+/HER2− Advanced Breast Cancer

Safety and Tolerability of the Next-Generation Oral SERD Camizestrant in Women With ER+/HER2− Advanced Breast Cancer

Epidemiology of Early vs Late Recurrence Among Women With Early-Stage ER+ Breast Cancer

Ipatasertib Plus Paclitaxel for PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic TNBC

Impact of Systemic Disease on CNS Disease Control After Stereotactic Radiosurgery to Breast Cancer Brain Metastases

Effect of PR Status on the Prognosis of Patients With Advanced ER-High HER2− Breast Cancer Receiving First-Line CDK4/6 Inhibitor Plus Endocrine Therapy

Effectiveness of ER-Targeted PET for Initial Staging and Evaluating Suspected Recurrence in ER-Positive Breast Cancer

Prognostic Value of the 21-Gene Breast Recurrence Score Assay for HR+/HER2− Advanced Breast Cancer

Recently Updated